Skip to main content
SpringerLink
Log in

Teaching an Old Dog New Tricks: Colchicine in Cardiovascular Medicine

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Colchicine is one of the oldest known drugs that remains part of the current pharmacopeia. Recent studies have examined the efficacy of colchicine in cardiology with promising results. We conducted a search of electronic databases for studies on colchicine in cardiovascular medicine published through October 2016. As the utilization of colchicine in the management of cardiac conditions grows, it is paramount that internists and cardiologists are familiarized with its benefits and risks. We present a comprehensive review of the role of colchicine in the management of cardiovascular diseases with a strong emphasis on side effects and potential drug interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Deftereos S, Giannopoulos G, Papoutsidakis N, et al. Colchicine and the heart: Pushing the envelope. J Am Coll Cardiol. 2013;62(20):1817–25. doi:10.1016/j.jacc.2013.08.726.

    Article  CAS  PubMed  Google Scholar 

  2. Nuki G. Colchicine: Its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 2008;10(3):218–27. doi:10.1007/s11926-008-0036-3.

    Article  CAS  PubMed  Google Scholar 

  3. Hemkens LG, Ewald H, Gloy VL, et al. Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev. 2016;1:CD011047. doi:10.1002/14651858.CD011047.pub2.

    Google Scholar 

  4. Verma S, Eikelboom JW, Nidorf SM, et al. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2015;15:96. doi:10.1186/s12872-015-0068-3.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Sapra S, Bhalla Y, Nandani SS, et al. Colchicine and its various physicochemical and biological aspects. Med Chem Res. 2013;22(2):531–47. doi:10.1007/s00044-012-0077-z.

    Article  CAS  Google Scholar 

  6. Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S. Colchicine: old and new. Am J Med. 2015;128(5):461–70. doi:10.1016/j.amjmed.2014.12.010.

    Article  CAS  PubMed  Google Scholar 

  7. Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013;61(25):2495–502. doi:10.1016/j.jacc.2013.02.058.

    Article  CAS  PubMed  Google Scholar 

  8. Leung YY, Yao Hui LL, Kraus VB. Colchicine: update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341–50. doi:10.1016/j.semarthrit.2015.06.013.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Casanova P, Artola RT, Mihos CG, Pineda AM, Santana O. The cardiovascular effects of colchicine: a comprehensive review. Cardiol Rev. 2015;23(6):317–22. doi:10.1097/CRD.0000000000000056.

    PubMed  Google Scholar 

  10. Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;35(27):1782–91. doi:10.1093/eurheartj/ehu203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the colchicine for acute pericarditis (COPE) trial. Circulation. 2005;112(13):2012–6. doi:10.1161/CIRCULATIONAHA.105.542738.

    Article  CAS  PubMed  Google Scholar 

  12. Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522–8. doi:10.1056/NEJMoa1208536.

    Article  CAS  PubMed  Google Scholar 

  13. Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155(7):409–14. doi:10.7326/0003-4819-155-7-201110040-00359.

    Article  PubMed  Google Scholar 

  14. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232–7. doi:10.1016/S0140-6736(13)62709-9.

    Article  CAS  PubMed  Google Scholar 

  15. Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165(17):1987–91. doi:10.1001/archinte.165.17.1987.

    Article  CAS  PubMed  Google Scholar 

  16. Adler Y, Charron P, Imazio M, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases. Eur Heart J. 2015;36(42):2921–64. doi:10.1093/eurheartj/ehv318.

    Article  PubMed  Google Scholar 

  17. Imazio M, Brucato A, Ferrazzi P, Spodick DH, Adler Y. Postpericardiotomy syndrome: a proposal for diagnostic criteria. J Cardiovasc Med (Hagerstown). 2013;14(5):351–3. doi:10.2459/JCM.0b013e328353807d.

    Article  Google Scholar 

  18. Imazio M, Trinchero R, Brucato A, et al. COlchicine for the prevention of the post-pericardiotomy syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J. 2010;31(22):2749–54. doi:10.1093/eurheartj/ehq319.

    Article  CAS  PubMed  Google Scholar 

  19. Imazio M, Brucato A, Ferrazzi P, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312(10):1016–23. doi:10.1001/jama.2014.11026.

    Article  CAS  PubMed  Google Scholar 

  20. Finkelstein Y, Shemesh J, Mahlab K, Abramov D, Bar-El Y, Sagie A, Sharoni E, Sahar G, Smolinsky AK, Schechter T, Vidne BAAY. Colchicine for the prevention of postpericardiotomy syndrome. Herz. 2002;27(8):791–4.

    Article  PubMed  Google Scholar 

  21. Fomaneg C, Samonte P, Sasondoncillo-Nadal M, Sim-Apura MCL, Padua L. Colchicine use for the primary prevention of postpericardiotomy syndrome (CUPP): a meta-analysis. Cardiology. 2014;128:475.

    Google Scholar 

  22. Miller RH, Horneffer PJ, Gardner TJ, Rykiel MF, Pearson TA. The epidemiology of the postpericardiotomy syndrome: a common complication of cardiac surgery. Am Heart J. 1988;116(5 Part 1):1323–9. doi:10.1016/0002-8703(88)90457-7.

    Article  CAS  PubMed  Google Scholar 

  23. Gunda S, Reddy M, Nath J, et al. Impact of periprocedural colchicine on postprocedural management in patients undergoing a left atrial appendage ligation using LARIAT. J Cardiovasc Electrophysiol. 2016;27(1):60–4. doi:10.1111/jce.12869.

    Article  PubMed  Google Scholar 

  24. Meurin P, Lelay-Kubas S, Pierre B, et al. Colchicine for postoperative pericardial effusion: a multicentre, double-blind, randomised controlled trial. Heart. 2015;101(21):1711–6. doi:10.1136/heartjnl-2015-307827.

    Article  CAS  PubMed  Google Scholar 

  25. Amoli A, Bozorgi A, HajHossein Talasaz A, et al. Efficacy of colchicine versus placebo for the treatment of pericardial effusion after open-heart surgery: A randomized, placebo-controlled trial. Am Heart J. 2015;170(6):1195–201. doi:10.1016/j.ahj.2015.09.020.

    Article  Google Scholar 

  26. John Camm A, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33(21):2719–47. doi:10.1093/eurheartj/ehs253.

    Article  PubMed  Google Scholar 

  27. Falk RH. Atrial Fibrillation. N Engl J Med. 2001;344(14):1067–78. doi:10.1016/j.emc.2011.08.008.

    Article  CAS  PubMed  Google Scholar 

  28. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol. 2011;57(11):e101–98. doi:10.1016/j.jacc.2010.09.013.

    Article  PubMed  Google Scholar 

  29. Lu YY, Chen YC, Kao YH, et al. Colchicine modulates calcium homeostasis and electrical property of HL-1 cells. J Cell Mol Med. 2016;20(6):1182–90. doi:10.1111/jcmm.12818.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Singhal R, Chang SL, Chong E, et al. Colchicine suppresses atrial fibrillation in failing heart. Int J Cardiol. 2014;176(3):651–60. doi:10.1016/j.ijcard.2014.07.069.

    Article  PubMed  Google Scholar 

  31. Koyama T, Sekiguchi Y, Tada H, et al. Comparison of characteristics and significance of immediate versus early versus no recurrence of atrial fibrillation after catheter ablation. Am J Cardiol. 2009;103(9):1249–54. doi:10.1016/j.amjcard.2009.01.010.

    Article  PubMed  Google Scholar 

  32. McCabe JM, Smith LM, Tseng ZH, et al. Protracted CRP elevation after atrial fibrillation ablation. Pacing Clin Electrophysiol. 2008;31(9):1146–51. doi:10.1111/j.1540-8159.2008.01155.x.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Deftereos S, Giannopoulos G, Kossyvakis C, et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol. 2012;60(18):1790–6. doi:10.1016/j.jacc.2012.07.031.

    Article  CAS  PubMed  Google Scholar 

  34. Deftereos S, Giannopoulos G, Efremidis M, et al. Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: mid-term efficacy and effect on quality of life. Heart Rhythm. 2014;11(4):620–8. doi:10.1016/j.hrthm.2014.02.002.

    Article  PubMed  Google Scholar 

  35. Tabbalat RA, Hamad NM, Alhaddad IA, Hammoudeh A, Akasheh BF, Khader Y. Effect of colchicine on the incidence of atrial fibrillation in open heart surgery patients: END-AF trial. Am Heart J. 2016;178:102–7. doi:10.1016/j.ahj.2016.05.006.

    Article  PubMed  Google Scholar 

  36. Saxena A, Shi WY, Bappayya S, et al. Postoperative atrial fibrillation after isolated aortic valve replacement: a cause for concern? Ann Thorac Surg. 2013;95(1):133–40. doi:10.1016/j.athoracsur.2012.08.077.

    Article  PubMed  Google Scholar 

  37. Saxena A, Kapoor J, Dinh DT, Smith JA, Shardey GC, Newcomb AE. Preoperative atrial fibrillation is an independent predictor of worse early and late outcomes after isolated coronary artery bypass graft surgery. J Cardiol. 2015;65(3):224–9. doi:10.1016/j.jjcc.2014.06.003.

    Article  PubMed  Google Scholar 

  38. Bruins P, Te VH, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96(10):3542–8. doi:10.1161/01.CIR.96.10.3542.

    Article  CAS  PubMed  Google Scholar 

  39. Ishii Y, Schuessler RB, Gaynor SL, et al. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation. 2005;111(22):2881–8. doi:10.1161/CIRCULATIONAHA.104.475194.

    Article  CAS  PubMed  Google Scholar 

  40. Imazio M, Brucato A, Ferrazzi P, et al. Colchicine reduces postoperative atrial fibrillation: results of the colchicine for the prevention of the postpericardiotomy syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011;124(21):2290–5. doi:10.1161/CIRCULATIONAHA.111.026153.

    Article  CAS  PubMed  Google Scholar 

  41. Sarzaeem M, Shayan N, Bagheri J, Jebelli M, Mandegar M. Low dose Colchicine in prevention of atrial fibrillation after coronary artery bypass graft: a double blind clinical trial. Tehran Univ Med J. 2014;72(3):147–54.

    Google Scholar 

  42. Zarpelon CS, Netto MC, Jorge JC, Fabris CC, Desengrini D, Silva DG. Colchicine to reduce atrial fibrillation in the postoperative period of myocardial revascularization. Arq Bras Cardiol. 2016;107(1):4–9. doi:10.5935/abc.20160082.

    PubMed  PubMed Central  Google Scholar 

  43. Lee JZ, Singh N, Howe CL, et al. Colchicine for prevention of post-operative atrial fibrillation: a meta-analysis. JACC Clin Electrophysiol. 2016;2(1):78–85. doi:10.1016/j.jacep.2015.09.016.

    Article  Google Scholar 

  44. Bessissow A. Colchicine for prevention of perioperative atrial fibrillation in patients undergoing thoracic surgery (COP-AF): pilot Study. Masters Thesis, Hamilton (ON): McMaster University; 2016. http://hdl.handle.net/11375/20112

  45. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2014;64(21):e1–76. doi:10.1016/j.jacc.2014.03.022.

    Article  PubMed  Google Scholar 

  46. Braunwald E. Heart failure. JACC Heart Fail. 2013;1(1):1–20. doi:10.1016/j.jchf.2012.10.002.

    Article  PubMed  Google Scholar 

  47. Sato H, Nagai T, Kuppuswamy D, et al. Microtubule stabilization in pressure overload cardiac hypertrophy. J Cell Biol. 1997;139(4):963–73. doi:10.1083/jcb.139.4.963.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Deftereos S, Giannopoulos G, Panagopoulou V, et al. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail. 2014;2(2):131–7. doi:10.1016/j.jchf.2013.11.006.

    Article  PubMed  Google Scholar 

  49. Crittenden DB, White CJ, DeBerardine M, et al. Colchicine is associated with a decreased rate of myocardial infarction in gout patients: Interim results from a retrospective cohort study. Arthritis Rheum. 2012;64:S71–2.

    Article  Google Scholar 

  50. Nochaiwong S, Ruengorn C, Panyathong S, Nanta S. Association of colchicine with primary and secondary cardiovascular events in peritoneal dialysis patients: a propensity score analysis. Value Health. 2014;17(7):A757. doi:10.1016/j.jval.2014.08.236.

    Article  CAS  PubMed  Google Scholar 

  51. Ridker PM. The JUPITER trial: Results, controversies, and implications for prevention. Circ Cardiovasc Qual Outcomes. 2009;2(3):279–85. doi:10.1161/CIRCOUTCOMES.109.868299.

    Article  PubMed  Google Scholar 

  52. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–504. doi:10.1056/NEJMoa040583.

    Article  CAS  PubMed  Google Scholar 

  53. Klingenberg R, Luscher TF. Inflammation in coronary artery disease and acute myocardial infarction - is the stage set for novel therapies? Curr Pharm Des. 2012;18(28):4358–69. doi:10.2174/138161212802481219.

    Article  CAS  PubMed  Google Scholar 

  54. Drakopoulou M, Toutouzas K, Michelongona A, Tousoulis D, Stefanadis C. Vulnerable plaque and inflammation: potential clinical strategies. Curr Pharm Des. 2011;17(37):4190–209.

    Article  CAS  PubMed  Google Scholar 

  55. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–10. doi:10.1016/j.jacc.2012.10.027.

    Article  CAS  PubMed  Google Scholar 

  56. Nidorf SM, Eikelboom JW, Thompson PL. Colchicine for secondary prevention of cardiovascular disease. Curr Atheroscler Rep. 2014;16(3):391. doi:10.1007/s11883-013-0391-z.

    Article  PubMed  Google Scholar 

  57. Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007;99(6):805–7. doi:10.1016/j.amjcard.2006.10.039.

    Article  CAS  PubMed  Google Scholar 

  58. Martinez GJ, Robertson S, Barraclough J, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc. 2015;4(8):e002128. doi:10.1161/JAHA.115.002128.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Huang C, Ceng C, Wang C, Zhan H, Ding X. Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia. Lipids Health Dis. 2014;13(1):67. doi:10.1186/1476-511X-13-67.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Shah B, Allen N, Harchandani B, et al. Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: a pilot study in healthy subjects. Inflammation. 2016;39(1):182–9. doi:10.1007/s10753-015-0237-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Faloon WW, Webb DI, Race TM. Cholesterol lowering effect of colchicine. Ann Intern Med. 1967;66(5):1058. doi:10.7326/0003-4819-66-5-1058_3.

    Article  Google Scholar 

  62. Ercolani LSW. Metabolic and morphologic effects of colchicine on human T-lymphocyte expression of Fc mu and Fc gamma receptors Title. Cell Immunol. 2014;77(2):222–32.

    Article  Google Scholar 

  63. Bauriedel G, Ganesh S, Uberfuhr P, Welsch U, Höfling B. Growth-inhibiting effect of colchicine on cultured vascular wall myocytes from arteriosclerotic lesions. Z Kardiol. 1992;81(2):92–8.

    CAS  PubMed  Google Scholar 

  64. Nidorf SM, Eikelboom JW, Budgeon C, Thompson PL. Low dose colchicine for secondary prevention of cardiovascular disease [LoDoCo]: a randomized controlled trial. Circulation. 2012;126(23):2787. doi:10.1161/CIR.0b013e318278c90d.

    Google Scholar 

  65. Raju NC, Yi Q, Nidorf M, Fagel ND, Hiralal R, Eikelboom JW. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: A pilot randomized controlled trial. J Thromb Thrombolysis. 2012;33(1):88–94. doi:10.1007/s11239-011-0637-y.

    Article  CAS  PubMed  Google Scholar 

  66. Deftereos S, Giannopoulos G, Angelidis C, et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. Circulation. 2015;132(15):1395–403. doi:10.1161/CIRCULATIONAHA.115.017611.

    Article  CAS  PubMed  Google Scholar 

  67. O’Keefe JH, McCallister BD, Bateman TM, Kuhnlein DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol. 1992;19(7):1597–600. doi:10.1016/0735-1097(92)90624-V.

    Article  PubMed  Google Scholar 

  68. Freed M, Safian RD, O’Neill WW, Safian M, Jones D, Grines CL. Combination of lovastatin, enalapril, and colchicine does not prevent restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1995;76(16):1185–8. doi:10.1016/S0002-9149(99)80334-8.

    Article  CAS  PubMed  Google Scholar 

  69. Deftereos S, Giannopoulos G, Raisakis K, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol. 2013;61(16):1679–85. doi:10.1016/j.jacc.2013.01.055.

    Article  CAS  PubMed  Google Scholar 

  70. Giannopoulos G, Angelidis C, Kouritas VK, et al. Usefulness of colchicine to reduce perioperative myocardial damage in patients who underwent on-pump coronary artery bypass grafting. Am J Cardiol. 2015;115(10):1376–81. doi:10.1016/j.amjcard.2015.02.036.

    Article  CAS  PubMed  Google Scholar 

  71. US Food and Drug Administration. Information for healthcare professionals: new safety information for colchicine (marketed as Colcrys). Silver Spring: US FDA; 2013.

    Google Scholar 

  72. US Food and Drug Administration/Center for Drug Evaluation and Research. Pharmacol Rev. 2009. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022352s000_PharmR.pdf

  73. Colcrys® (colchicine) oral tablets: US prescribing information. Philadelphia: Mutual Pharmaceutical Company, Inc.; 2009.

  74. Chung ES, Packer M, Lo KH, Fasanmade AA. Anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107:3133–40.

    Article  CAS  PubMed  Google Scholar 

  75. Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63(8):2226–37. doi:10.1002/art.30389.

    Article  CAS  PubMed  Google Scholar 

  76. Davis MW, Wason S. Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions. Clin Drug Investig. 2014;34(4):259–67. doi:10.1007/s40261-013-0168-8.

    Article  CAS  PubMed  Google Scholar 

  77. Sahin G, Korkmaz C, Yalcin AU. Which statin should be used together with colchicine? Clinical experience in three patients with nephrotic syndrome due to AA type amyloidosis. Rheumatol Int. 2008;28(3):289–91. doi:10.1007/s00296-007-0435-1.

    Article  PubMed  Google Scholar 

  78. Alayli G, Cengiz K, Cantürk F, Durmuş D, Akyol Y, Menekşe EB. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother. 2005;39(7–8):1358–61. doi:10.1345/aph.1E593.

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Internal Medicine Department, Cleveland Clinic, Cleveland, OH, 33195, USA

      Kevin Chen

    2. Cardiovascular Medicine Department, Cleveland Clinic, Cleveland, OH, 33195, USA

      Aldo L. Schenone, Nyal Borges & Venu Menon

    3. Pharmacy Department, Cleveland Clinic, Cleveland, OH, 33195, USA

      Michael Militello

    Authors
    1. Kevin Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Aldo L. Schenone
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Nyal Borges
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Michael Militello
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Venu Menon
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Aldo L. Schenone.

    Ethics declarations

    Conflicts of interest

    None of the authors involved with this manuscript have any financial or personal relationships with other people or organizations that could inappropriately influence or bias their work. Therefore, Kevin Chen, Aldo L. Schenone, Nyal Borges, Michael Militello, and Venu Menon have no conflicts of interest that might be relevant to the contents of this manuscript.

    Funding

    No external funding was used in the preparation of this manuscript.

    Author Contributions

    Kevin Chen, Aldo Schenone, Nyal Borges, and Venu Menon contributed substantially to the conception and design of the work. All authors were responsible for drafting and key revisions to this manuscript. All authors have approved the final version of the manuscript and are accountable for all aspects related to the accuracy or integrity of this manuscript.

    Additional information

    K. Chen and A. L. Schenone contributed equally in the manuscript.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Chen, K., Schenone, A.L., Borges, N. et al. Teaching an Old Dog New Tricks: Colchicine in Cardiovascular Medicine. Am J Cardiovasc Drugs 17, 347–360 (2017). https://doi.org/10.1007/s40256-017-0226-3

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40256-017-0226-3

    Keywords

    Search

    Navigation